Table 4 Top five pathways (p < 0.01) predicted by IPA for Fayoumi vs. Leghorn in different treatment groups.
Group | Pathways | Important DEGs contributing to prediction | Ratios |
|---|---|---|---|
Control 2 dpi | IL-8 signaling | FGFR(1/3), PIK3C(G/2 G),GNG(2/10) | 29/197 |
Production of nitric oxide and reactive oxygen species in macrophages | PIK3C(G/2 G), FGFR(1/3) , NCF(1/2/4) | 25/193 | |
STAT3 pathway | PDGFR(A/B), FLT(1/4), FGFR(1/3/L1) | 17/73 | |
Sumoylation pathway | FAS, FASLG, SENP1, RHOJ , CBX4 | 15/96 | |
Sphingosine-1-phosphate Signaling | FGFR(1/3), PDGFA, PIK3C(G/2 G) | 17/123 | |
NDV 2 dpi | mTOR signaling | ATG13, EIF3D/F/L/M, EIF4EBP1 | 35/199 |
Regulation of eIF4 and p70S6K signaling | PABPC1, EIF3(D/F/L/M), EIF4EBP1 | 29/157 | |
EIF2 signaling | PABPC1, EIF3(D/F/L/M), EIF2S3 | 36/221 | |
IL-8 signaling | FGFR(2/3), PIK3C(G/2 G), RHOB | 29/197 | |
Production of nitric oxide and reactive oxygen species in macrophages | STAT1, PIK3C(G/2 G), FGFR(2/3) | 28/193 | |
Control 6 dpi | Coagulation system | F7, F10, FGB, SRPINF2, BDKRB1 | 9/35 |
Leukocyte extravasation signaling | ACT(A1/A2/G2), FGFR(2/3), PIK3C2G | 23/210 | |
Th2 pathway | PIK3C2G, CD(4/28), FGFR(2/3), DLL1 | 16/150 | |
Paxilin signaling | ACT(A1/A2/G2), FGFR(2/3), PIK3C2G , | 13/113 | |
Acute myeloid leukemia signaling | PIK3C2G, KLB, FGFR(2/3), KIT | 11/91 | |
NDV 6 dpi | Complement system | C1S, C1R, C8B, CFD, MBL2 | 5/37 |
eNOS signaling | VEGFD, FGFR3, PIK3C2G , CNGA3 | 11/155 | |
PCP pathway | WNT5A, RSPO3, CELSR1, FZD(3/5) | 6/63 | |
Oncostatin M signaling | MMP(1/3), PLAU | 4/34 | |
Coagulation system | SRPINF2, F13A1, PLAU , TFPI | 4/35 |
